Tesamorelin — The Peptide for Visceral Fat, Metabolic Health, and Why Monitoring Matters

A lot of patients come in frustrated by abdominal fat. Not just “I want to look better in jeans” fat, but the deeper, firmer, more metabolically active abdominal fat that sits around the organs. That type of fat is called visceral adipose tissue, and it behaves very differently from the soft fat under the skin.

Visceral fat is more inflammatory. It is more hormonally active. It is more closely tied to insulin resistance, cardiometabolic risk, fatty liver patterns, and that stubborn “hard belly” that does not always respond the way people expect.

Tesamorelin is a peptide that deserves a careful conversation in that context.

Tesamorelin is a growth hormone-releasing hormone analog. In plain English, it signals the pituitary gland to release more of your own growth hormone, which then increases IGF-1 signaling. It is not the same as injecting growth hormone. It is upstream of that process. The FDA-approved medication EGRIFTA WR, which contains tesamorelin, is indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. The prescribing information also clearly states that it is not for weight loss management.

That distinction matters.

Tesamorelin is not a vanity shot. It is not a GLP-1. It is not a “melt fat while you keep doing everything else wrong” medication. It works through growth hormone biology, and that means it requires respect, screening, labs, and follow-up.

What the science shows

In clinical research involving HIV-infected patients with abdominal fat accumulation, tesamorelin has been shown to reduce visceral adipose tissue. In one randomized clinical trial published in JAMA, tesamorelin significantly reduced visceral fat and modestly reduced liver fat over six months compared with placebo.

That is why this peptide gets attention beyond its FDA-approved indication. Patients and clinicians are interested in the possibility of improving body composition, visceral fat burden, and metabolic patterns. But off-label interest does not remove the need for caution. Growth hormone and IGF-1 pathways are powerful. Powerful tools can help the right patient and hurt the wrong one.

Who may be a good candidate for a tesamorelin discussion?

Tesamorelin may be worth discussing for patients who have signs of visceral adiposity and metabolic dysfunction, especially when lifestyle alone is not giving adequate results. Examples may include:

• Patients with central abdominal fat that appears more visceral than subcutaneous.
• Patients with metabolic risk patterns such as insulin resistance, elevated waist circumference, fatty liver tendencies, or poor body composition.
• Patients who are already doing the fundamentals: protein intake, resistance training, sleep, blood sugar control, alcohol moderation, and stress management.
• Patients who understand this requires lab monitoring, not guessing.
• Patients who are not looking for a “quick fix,” but for a medically guided strategy.

The key phrase is medically guided. Tesamorelin affects growth hormone and IGF-1 signaling. That means we need to know what is going on with your glucose, insulin sensitivity, cancer history, fluid retention risk, medications, and overall health.

Who should not use tesamorelin?

Tesamorelin is not appropriate for everyone. Based on prescribing information for EGRIFTA WR, it is contraindicated in patients with disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy. The label also warns about increased IGF-1 levels, fluid retention, glucose intolerance or diabetes, hypersensitivity reactions, injection site reactions, and increased mortality risk in acute critical illness related to certain growth hormone contexts.

In practical clinic language, I would be very cautious or say no in patients with:

• Active cancer or unresolved cancer evaluation.
• Recent cancer history without specialist clearance.
• Pregnancy or plans to become pregnant.
• Poorly controlled diabetes or worsening diabetic eye disease.
• Significant edema, carpal tunnel symptoms, or fluid retention.
• Pituitary tumors, pituitary surgery, head radiation, or major pituitary disorders.
• Acute critical illness, major trauma, or unstable medical conditions.
• Unrealistic expectations or unwillingness to do follow-up labs.

The label notes that tesamorelin increases IGF-1 and recommends monitoring IGF-1 during therapy. It also recommends glucose evaluation before and during therapy because glucose intolerance or diabetes can develop.

That is why I do not like casual peptide use. It is not that peptides are scary. It is that people treat them too casually.

The online peptide problem

Tesamorelin is a perfect example of why sourcing matters. A peptide is not just a name on a label. It has to be the correct molecule, at the correct strength, sterile if injected, stored correctly, and used in the right patient.

When someone orders a peptide from a random online site, they are trusting a stranger with their endocrine system and overall health safety. That is a big leap of faith.

Here is what you do not know with an unregulated source:

• Is it actually tesamorelin?
• Is the dose accurate?
• Is it sterile?
• Does it contain contaminants or peptide impurities?
• Was it stored correctly?
• Was it shipped correctly?
• Is the “certificate of analysis” real, current, and batch-specific?
• Does anyone know your medical history before you inject it?

FDA has warned that compounded drugs are not FDA-approved and that poor-quality compounded drugs can cause serious injury or death if contaminated or incorrectly made. That is why legitimate medical sourcing, pharmacy accountability, and physician oversight matter so much.

At Recharge, we do not approach peptides like a trend. We approach them like medical tools. When appropriate, we source through regulated, licensed pharmacy channels and monitor patients clinically. The difference between that and an online mystery vial is not a small detail. That is the whole point.

My bottom line on tesamorelin

Tesamorelin may be a valuable option for the right patient, especially when visceral fat and metabolic health are part of the concern. But it is not for casual weight loss, not for pregnancy, not for active cancer, and not for people who do not want labs.

Used correctly, tesamorelin is a medical conversation. Used recklessly, it is endocrine gambling.

And I do not want my patients gambling with their hormones.

How do I schedule at Recharge Clinic?

Scheduling with Recharge Clinic is simple.

You can call 352-512-9996 or book an appointment online through the Recharge Clinic website. Recharge also welcomes walk-ins at select locations, depending on the service and availability.

When you schedule, let the team know you are interested in learning more about peptides. From there, we can help guide you through the next steps, review your labs, and discuss what may be appropriate for you.

Continue the Peptide Series

Missed the first blog?

Start here: KPV Peptide — Calming the Fire of Inflammation Without Playing Internet Roulette

Coming Up Next:

Wolverine, BPC-157, and KLOW — Recovery Peptides Are Not Magic, and They Are Definitely Not DIY

Whether you're exploring peptides for inflammation, metabolic health, or recovery, understanding the science, the risks, and the importance of proper medical supervision is essential. Be sure to follow the full series as Dr. Tieche breaks down what these therapies can—and cannot—do.

FAQ: Tesamorelin for Visceral Fat and Metabolic Health

1. Is Tesamorelin a weight-loss shot?

No. Tesamorelin is not a general weight-loss shot, and I do not want patients thinking of it that way. Tesamorelin is a growth hormone-releasing hormone analog that signals the body to release more of its own growth hormone, which then affects IGF-1. The FDA-approved tesamorelin product, EGRIFTA WR, is used to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and its labeling states that it is not for weight loss management.

2. Who might benefit from talking about tesamorelin?

Tesamorelin may be worth discussing for patients with central abdominal fat that appears more visceral, especially when that fat is connected with metabolic concerns like insulin resistance, poor body composition, or fatty liver tendencies. It is best suited for patients already doing the fundamentals: resistance training, protein intake, sleep, blood sugar control, stress management, and alcohol moderation. This is not a “do nothing and lose fat” option. It is a medical tool that requires evaluation and monitoring.

3. What labs or monitoring are important with tesamorelin?

Because tesamorelin affects growth hormone and IGF-1 signaling, monitoring matters. Patients may need baseline and follow-up evaluation of IGF-1, fasting glucose, A1C, insulin resistance markers, and overall metabolic health. The prescribing information for EGRIFTA WR warns that it can increase IGF-1, may cause fluid retention, and can contribute to glucose intolerance or diabetes. That is why I do not like casual use. If we are going to influence hormone pathways, we need to measure and monitor.

4. Who should not use tesamorelin?

Tesamorelin is not appropriate for patients with active cancer, pregnancy, known hypersensitivity to tesamorelin, or disruption of the hypothalamic-pituitary axis. I would also be cautious in patients with a history of cancer, uncontrolled diabetes, worsening diabetic eye disease, significant swelling, carpal tunnel symptoms, or unstable medical conditions. The prescribing information specifically warns about active malignancy, elevated IGF-1, fluid retention, glucose intolerance, hypersensitivity reactions, injection site reactions, and critical illness concerns.

Educational Disclaimer

This blog is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Tesamorelin is not appropriate for everyone and should only be used under the supervision of a qualified healthcare provider. Treatment decisions should be based on an individual's medical history, laboratory evaluation, current medications, and overall health. Never use peptide therapies without proper medical guidance or purchase them from unregulated online sources.

References

1. DailyMed. EGRIFTA WR — tesamorelin prescribing information. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75 
2. Stanley TL, et al. Effect of Tesamorelin on Liver Fat and Visceral Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial. JAMA. https://jamanetwork.com/journals/jama/fullarticle/1889139 
3. FDA. Understanding the Risks of Compounded Drugs. https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs 
4. FDA. Human Drug Compounding Laws. ​​https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws 
5. FDA. BeSafeRx: Your Source for Online Pharmacy Information. https://www.fda.gov/drugs/besaferx-your-source-online-pharmacy-information/about-besaferx 

Want to learn more about peptide therapy?

Join us for our FREE Wellness Talk: Recovery Peptides: Healing Beyond Traditional Medicine

📅 Wednesday, July 8, 2026
🕕 6:00 PM – 7:00 PM
📍 Recharge Clinic
47 SW 17th St., Ocala, FL 34471

Can't make it in person? Join us live on Zoom!
👉 Reserve your spot: https://lp.constantcontactpages.com/sl/ALdwL3u/WTRecoveryPeptides